Nasdaq · Healthcare
HUTCHMED (China) Ltd (HCM)
As-reported financials and recent SEC filings for HUTCHMED (China) Ltd, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$548.5M
Net income
$456.9M
Net margin
83.3%
Diluted EPS
$0.52
ROE
36.5%
P/E (TTM)
3.8×
Market cap
$1.75B
Debt / equity
0.1×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $548.5M | $630.2M | $838.0M | $426.4M | $356.1M |
| Gross profit | $212.2M | $281.3M | $453.6M | $115.3M | — |
| Operating income | $-39.2M | $-43.7M | $18.4M | $-407.7M | $-328.3M |
| Net income | $456.9M | $37.7M | $100.8M | $-360.8M | $-194.6M |
| Diluted EPS | $0.52 | $0.04 | $0.12 | $-0.43 | $-0.25 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
6-K2026-06-25
View on EDGAR →6-K2026-06-12
View on EDGAR →S-82026-06-09
View on EDGAR →6-K2026-06-05
View on EDGAR →6-K2026-05-22
View on EDGAR →6-K2026-05-21
View on EDGAR →42026-05-21
View on EDGAR →42026-05-21
View on EDGAR →Go deeper on HCM
Search HUTCHMED (China) Ltd’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.